Garcia et al. discover a novel immunotherapy approach by engineering naturally occurring mutations in therapeutic T cells to strongly elevate anti-tumor activity. The authors identify a gene fusion, CARD11-PIK3R3, to increase activator protein 1 and nuclear factor-κB signaling, interleukin-2 production, and tumor death in vitro and in vivo .
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11215281 | PMC |
| http://dx.doi.org/10.1002/mco2.628 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Garcia et al. discover a novel immunotherapy approach by engineering naturally occurring mutations in therapeutic T cells to strongly elevate anti-tumor activity. The authors identify a gene fusion, CARD11-PIK3R3, to increase activator protein 1 and nuclear factor-κB signaling, interleukin-2 production, and tumor death in vitro and in vivo .
View Article and Find Full Text PDFUnveiling a novel fusion gene enhances CAR T cell therapy for solid tumors.
Mol Cancer
May 2024
Department of Clinical Medicine, Hangzhou City University, Hangzhou, Zhejiang, China.
Article Synopsis
- Scientists are studying a new treatment called Adoptive Cell Transfer Therapy (ACT) for solid tumors, which hasn't worked as well as for blood cancers.
- A recent study by Garcia and colleagues found that adding a special gene called CARD11-PIK3R3 to T cells can make them better at fighting tumors.
- This new approach could reduce the amount of T cells needed and may help treat solid tumors safely, but more research is needed to understand how well it works in the long run.
Naturally occurring T cell mutations enhance engineered T cell therapies.
Nature
February 2024
Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Adoptive T cell therapies have produced exceptional responses in a subset of patients with cancer. However, therapeutic efficacy can be hindered by poor T cell persistence and function. In human T cell cancers, evolution of the disease positively selects for mutations that improve fitness of T cells in challenging situations analogous to those faced by therapeutic T cells.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!